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Background: Lymphoid infiltration is a prognostic marker in solid tumors, such as colorectal, breast and lung
carcinomas. However, lymphoid infiltration is heterogeneous and the reproducibility of quantification based on
single counts within a tumor is very low. We aimed to develop a reproducible method for evaluating lymphoid
infiltration in tumors.
Methods: Virtual slides were obtained from tissue sections from the localized colorectal carcinomas of 117 patients,
stained for CD3 and CD45R0. We assessed the variation of lymphoid cell density by automatic counts in 1 mm-
wide, 5 μm-long segments of the invasive front, along an axis 4 mm in length running perpendicular to the
invasive front of the tumor.
Results: We plotted curves of the variation of lymphocyte density across the tumor front. Three distinct patterns
emerged from this linear quantification of lymphocyte (LQLI). In pattern 1, there was a high density of lymphocytes
within the tumor. In pattern 2, lymphocyte density peaked close to the invasive margin. In pattern 3, lymphocytes
were diffusely distributed, at low density. It was possible to classify all the tumors studied, and interobserver
reproducibility was excellent (kappa =0.9). By contrast, single counts of CD3+ cells on tissue microarrays were highly
variable for a given LQLI pattern, confirming the heterogeneity of lymphoid infiltration within individual tumors. In
univariate analysis, all pathologic features (stage, metastatic lymph node ratio (LNR), vascular embolism, perineural
invasion), CD3+ cell density, LQLI patterns for CD3+ and CD45R0+ cells) were found to have a significant effect on
disease-free survival (DFS). In multivariate analysis, only the LQLI pattern for CD3+ cells (HR: 6.02; 95% CI: 2.74-13.18)
and metastatic lymph node ratio (HR: 6.14; 95% CI: 2.32-16.2) were associated with DFS.
Conclusion: LQLI is an automated, reproducible method for the assessment of lymphoid infiltration. However,
validation of its prognostic value in larger series is required before its introduction into routine practice for
prognostic evaluation in patients with colorectal carcinomas.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/9861460717895880
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It is now clearly established that tumor progression depends
not only on the biological characteristics of the tumor, but
also on the host immune response to the tumor [1,2]. More
than four thousand papers have been published on the im-
mune response and carcinomas over the last 40 years. Most
studies of this aspect in solid cancers, mostly colorectal car-
cinoma (CRC), lung and breast cancers, reported a strong
correlation between the density of immune cells, particularly
lymphocytes, within tumors and long-term survival [3-10].
However, despite this massive body of evidence, lymphocyte
infiltration (LI) is not taken into account in daily practice,
even for discussions of adjuvant treatment in patients with
stage II or III CRC. This paradox is explained by the lack of
a reproducible and suitable method for assessing LI. There
is, therefore, a need to develop new, more reproducible
methods for LI assessment.
Immune cell density is evaluated on slides stained with
hematoxylin and eosin (H&E) or by in situ immunohis-
tochemistry on tumor samples, performed on whole
slides or tissue microarrays (TMA) [11]. In early studies
of lymphocyte infiltration, the pathologists counted the
lymphocytes within a limited area of the tumor them-
selves, by eye [3,4]. However, this method was time-
consuming and subject to human error, the area of the
tumor considered was small and reproducibility between
pathologists was poor. The more recent development of
a combination of virtual slide technology and image ana-
lysis software has made high-throughput counting pos-
sible. This approach has been adopted by several
authors, mostly using TMA [5,12]. Lymphocyte density
is classified as “high “or “low”, depending on whether
the absolute number of lymphocytes obtained is higher
or lower than the mean absolute number of lymphocytes
for the study population.
TMA-based approaches are cheap and pertinent in
this field, but the area analyzed is limited to the size of
the TMA core (diameter of 0.6 mm in most studies).
Furthermore, LI is highly heterogeneous within tumors,
rendering lymphocyte counts in limited areas highly va-
riable. The establishment of a cutoff value for lymphocyte
density for the estimation of prognosis is, thus, necessarily
biased, and the assessment of tumor lymphoid infiltration
based on absolute values for restricted areas is unsatisfac-
tory. The aim of this study was to develop a reproducible
method for LI quantification, overcoming these problems
of variability.
Recent studies of CRC have shown that the prognostic
value of LI determinations can be increased by combining
lymphocyte densities within and outside the tumor. This
suggests that the environment immediately around the
tumor should be included in the evaluation of LI [13].
Based on these findings and the need to limit the bias
described above, any method for measuring LI must takelarge areas of tissue sections, including both tumor tis-
sue and the adjacent region, into account. Such methods
should also involve automated counting, based on image
analysis, to save time and to overcome potential pro-
blems of interobserver variability.
We focused on the CRC CD3+ and CD45R0+ lympho-
cyte subpopulations for the development of this method,
because infiltration with these subpopulations has been
widely reported to have an impact on the outcome of
CRC [11,13]. We plotted curves of infiltration along an
axis running parallel to the invasive front of the tumor
and looked for common patterns in a sample of CRC.
We then assessed the prognostic value of this method by
comparing the results obtained with those for the prog-
nostic markers used in routine practice and with single
counts of CD3+ cells on TMA.
Methods
The first step in this study was the establishment of the
linear quantification of lymphocyte infiltration (LQLI)
method.
Samples
H&E-stained slides of CRC sections were checked for
the presence of an invasive tumor front. Formalin-fixed
paraffin-embedded (FFPE) blocks containing tumor tis-
sue with an invasive front and surrounded tissue were
selected for the construction of TMA and the applica-
tion of our quantification method (see below; Figure 1).
Paraffin-embedded samples were obtained from the
Pathology Department and the tissue bank of Ambroise
Paré Hospital, which has been registered with the French
Ministry of Research (# DC 2009–933).
Immunohistochemistry
Immunohistochemistry was performed on 4 μm-thick sec-
tion of FFPE tissue samples, with a Bond autostainer
(Leica, Biosystems Newcastle Ltd), after antigen retrieval
in citrate buffer pH6 (Leica, Biosystems Newcastle Ltd)
and endogenous peroxidase inhibition with 3% H2O2. The
primary antibodies were mouse monoclonal anti-CD3
(1/50, clone F7.2.38, Dako France S.A.S.) and anti-CD45R0
(1/50; clone UCHL1, Dako France) antibodies. Antibody
binding was detected and the signal was amplified with the
Bond Polymer Refine Detection system (Leica, Biosystems
Newcastle Ltd) and hematoxylin counterstaining.
Linear quantification of lymphoid infiltration of the tumor
front
Support
Virtual slides were obtained by scanning each slide with
Mirax Desk (Zeiss, Germany) and quality control with
Miraxviewer software (Zeiss, Germany). Images were
analyzed with Visilog 9.0 software (Noesis, Saclay,
Figure 1 In situ immunohistochemistry with brown staining of
CD3 lymphocytes and blue nuclear staining of all cells
including the invasive front (arrows) of a colon
adenocarcinoma (CA). The rectangle represents surface of analysis
of our method and dotted circle correspond to TMA core (0.6mm).
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already used in a previous study [14].
Concept
Visilog 9.0 software was specifically developed to express
lymphocyte density as a function of the distance from
the invasive front of the tumor, defined as the micro-
scopic interface between the normal tissue of the host
and the tumor mass. In budding tumors, the tumor front
was localized close to areas containing groups of at least
five cohesive tumor cells. Lymphocyte density was evalu-
ated from the outside to the inside of the tumor, along
an axis perpendicular to the tangent of the invasive front
of the tumor.
The area analyzed was a rectangle (1 mm × 4 mm),
measuring 4 square millimeters (Figure 1). The invasive
front of the tumor was manually positioned, by the ob-
server, in the middle of the rectangle, with the tumor to
the right. Lymphocyte cell density was determined for
segments of 5 μm. CD3+ cells were counted as a func-
tion of their distance from the invasive front of the
tumor, in 5 μm segments from the outside to the inside
of the tumor (Figure 2). We named this method the lin-
ear quantification of lymphocyte infiltration (LQLI). As
counts were standardized for an area 1 mm wide, each
lymphocyte density value corresponded to an area of
5000 μm2, and was associated with a distance from the
invasive front of the tumor. We then plotted curves oflymphocyte density from the outside to the inside of the
tumors, across the invasive front (Figure 2). We ensured
that these curves were comparable between patients by
positioning the curve on the axes such that the region
surrounding the tumor extended from 0 to 2 mm and
the tumor region extended from 2 mm to 4 mm.
Process
In practice, the process was performed as follows:
1. Opening the file for the virtual slide in .mrx or .vms
format
2. Automatically generating a 1 × 4 mm rectangle, with
preformatted counting areas, measuring 1 mm ×
5 μm, along an axis running perpendicular to the
tumor front
3. Orienting the rectangle and positioning it manually
on the virtual slide
4. The simultaneous use of several rectangles on the
same virtual slide was possible
5. Automatic detection of lymphocytes based on a
three-step process: i) detection based on color
thresholding; ii) boundary definition with a
watershed approach and iii) filtering on the
detected elements on the basis of size
6. Visual validation of the identified lymphocytes. It is
possible to modify the default parameters
beforehand (size, blue intensity, red intensity), if
necessary, and to check corresponding results as
many times as necessary. The three parameters
listed here were identified as the most critical
during the evaluation of robustness.
7. Up to 100 slides can be prepared before automatic
counting.
8. Automatic counting of the lymphocytes in 5 μm
segments at known distances from the tumor front.
Processing time of 40 to 200 seconds per slide,
depending on the number of rectangles and the
computer used.
9. Automatic generation of a curve of distance from
the tumor front (x) versus lymphocyte count (y).
The curves for the various rectangles can be merged
and used to generate a curve of mean counts.
Manual export of the data in .csv format is possible,
for further analyses.
We then compared the prognostic value of LQLI with
those of widely used clinical/pathologic parameters, and with
CD3+ lymphocyte densities determined from TMA cores.
CD3+ lymphocyte densities measured with tissue
microarrays
TMA blocks were constructed as follows: three cores,
each with a diameter of 0.6 mm, were taken from the
Figure 2 Linear quantification of lymphocytes (LQL) was
performed on virtual slides (A) on one to eight rectangles of
1x4 mm placed across the tumor invasive front. Each selected
area was perpendicular to the invasive front, and the 2 mm of
tumor were always to the right (B). CD3 positive cells (green stain)
were identified by image analysis (C). Control was performed by
comparing both images (B and C). Automated quantification of
lymphocyte density was then performed every 5 μm from 2 mm
outside to 2 mm inside the tumor, on 2 to 8 selected areas of the
tumor. Each value corresponded to a surface of 500 μm2, and was
associated with the distance from the tumor invasive front,
corresponding to the x and y axis of the curve respectively. Each of
the different colored curves (blue, green, red) is issued from one
area of measurement (D). These different curves lead to a mean
curve, which was used for the identification of the LQL pattern (E).
The number of area of measurement varies from two to eight
depending on the size of the tumor invasive front.
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generated from another FFPE block of the same tumor.
A manual tissue-array instrument (Beecher Instruments,
Alphelys, Plaisir, France) was used to insert each core
into the recipient paraffin block. All positive cells within
each core were counted automatically and a mean value
for the three cores was obtained in square millimeters
and used for statistical analysis.
Evaluation cohort
We studied 117 consecutive patients with stage II and III
colorectal cancer (International Union Against Cancer
[UICC], TNM classification) undergoing “en bloc” resec-
tion between January 1998 and December 2008 at
Ambroise Paré Hospital (Table 1). Patients with stage II
and III CRC constitute a heterogeneous group with a risk
of relapse of 15 to 60%, for which improvements in the
assessment of prognosis would be of clinical benefit,
particularly as concerns decisions relating to adjuvant
therapy. None of the patients with stage II CRC received
adjuvant treatment. All patients with stage III CRC com-
pleted six months of a FOLFOX adjuvant therapy regi-
men, in accordance with international recommendations
[15,16].
The cohort was rendered more homogeneous co-
hort by the exclusion of patients undergoing palliative
resection, or with tumor perforation, a personal his-
tory of familial adenomatous polyposis coli, previous
chemotherapy and radiotherapy or a tumor of the low
or mid rectum.
Follow-up consisted of a physical examination, carci-
noembryonic antigen (CEA) determination, CT scan or
the thorax and abdomen and/or abdominal ultrasound
and chest X ray every three months for the first three
years and every six months for two years, as recom-
mended in the Guidelines of the French Society for
Gastroenterology, 2008).
This study was approved by the relevant ethics com-
mittee, CPP Ile de France 8 (DC 11 05 45).
Pathology data
All patients included were reviewed for pathological
features by two pathologist expert in digestive oncol-
ogy (CJ & JFE). Immunostaining for mismatch repair
proteins was carried out to diagnose microsatellite
instability (MSI) as previously reported [17]. Table 1
summarizes clinical and pathological characteristics
of the cohort.
Statistical analysis
Interobservation reproducibility was assessed by calcula-
ting the kappa coefficient. The means of three populations
were compared by non parametric Kruskal-Wallis tests.
Table 1 Description of the study population
Clinical & pathological characteristics No.




Mean (s.d.) follow-up (months) 57 (±25)

















The values shown in brackets are percentages, unless otherwise indicated.
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point for prognostic assessment. DFS has been shown
to be an appropriate surrogate end-point for overall
survival in studies of nonmetastatic colorectal cancer
[18]. In survival analysis, we also assessed widely used
prognostic factors such as TNM stage, metastatic
lymph node ratio (LNR) [19], MSI status, vascular em-
bolism and perineural invasion. We also included the
CD3+ cell density measured on TMA (Patients were
classified as “High LI density” or “Low LI density” with
respect to the mean lymphoid density measured with
TMA), and LQLI pattern with immunostaining for
CD3 and CD45R0. The failure event for DFS analysis
was defined as death or relapse. Survival time was cal-
culated from the date of surgery to the date of the
failure event or last follow-up. The significance of the
effect of the variables tested on DFS was assessed by
univariate analysis, with log-rank tests. We used a Cox
proportional hazards model to assess the prognostic
value of all variables identified as significant in univa-
riate analysis. A P value ≤ 0.1 was required for entry
into the model. Statistical significance was indicated by
a P value < 0.05. The analysis was conducted with R
software (2.14.1), except for Kaplan-Meier curves,
which were plotted with IBM SPSS Statistics 20.Results
LQLI patterns for CD3+cells
It was possible to apply the LQLI method to all tumors.
The LQLI curves for each tumor were all very similar,
suggesting that tumors had a specific pattern of lym-
phoid cell density variation across the invasive front.
We then tried to define groups of tumors with similar
LQLI. Comparisons of the curves obtained led to the iden-
tification of three distinct patterns. In the first (pattern 1),
lymphocyte density was higher within the tumor than in
the region surrounding the tumor. This pattern accounted
for 21% of the study population (Figure 3; A, B).
The second pattern was marked by the existence of a
significant peak in the invasive front region. This feature
corresponded to the presence of large numbers of lym-
phocytes in the close vicinity of the tumor. Lymphocyte
density increased just ahead of the invasive front, at a
mean distance of 400 μm ahead of this front, and
declined in the 200 μm beyond the invasive front. This
pattern was observed in 61% of patients. The height of
the peak was varied considerably between patients, from
3 to 14 CD3+ cells/5000 μm2 (Figure 3; C, D, E, F) with
a mean value of 6.7 CD3+ cells/5000 μm2.
In the third pattern, the density of CD3+ lymphocytes
was low throughout the tumor front, with no significant
fluctuation. This pattern was detected in 18% of the
patients (Figure 3; G, H).LQLI pattern for CD45R0+ cells
The same three LQLI patterns were observed with
CD45R0 immunostaining.
In 104 patients (89%), the type of LQLI pattern was iden-
tical with both antibodies. Discrepancies between the LQLI
pattern for a given tumor were observed in 13 patients
(11%) and mostly concerned patterns 2 and 3 (Table 2).Heterogeneity of tumor lymphoid infiltration
Mean lymphocyte density, as assessed by automatic count-
ing on TMA, was 612 CD3+ cells/mm2 (range, 21 to 3014).
Mean CD3+ cell densities were 922/mm2 (range, 132 to
3014), 581/mm2 (21 to 1768) and 392/mm2 (67 to
846) for patients displaying LQLI patterns 1, 2 and 3,
respectively. The differences between the mean CD3+
cell densities for these three patterns were significant
(P = 0.002; Figure 4).
The fluctuations in the parts of the curve correspond-
ing to the tumor and the surrounding tissue highlighted
the considerable variability of The maximal/minimal
tumor CD3+ cell density ratio within each tumor ranged
from 2.5 to 55, with a median value of 14.5. Heteroge-
neity was lower at greater distances from the invasive
tumor front. Indeed the median maximal/minimal CD3+
cell density ratios for points 1.5 mm outside and 2 mm
Figure 3 Left side (A, C, E, G): Curves derived from different measures performed on 4 tumors. Right side (B, D, F, H): Different pattern of
lymphocytic infiltration defined according to the mean curve derived from the different measures in A, C, E and G respectively. Pattern 1: High
density of positive lymphocytes within the tumors (A, B). Pattern 2: High Peak of lymphocyte density within the non-tumorous tissues localized
nearby the tumors (C, D) and Low Peak of lymphocyte density within the non-tumorous tissues localized nearby the tumors (E, F). Pattern 3:
Uniform low lymphocyte density (G, H).
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respectively (Figure 5).
Reproducibility
The robustness of the method was confirmed by analy-
zing sections from different paraffin-embedded blocks
for a given tumor, carrying out CD3 immunostaining
separately on several sections of a given block and gene-
rating several virtual slides by multiple scans of a small
number of slides. We found that LQLI measurements at
different points along the length of the tumor front had
no effect on the pattern observed (Figure 2).
The reproducibility of pattern classification was assessed
by the analysis of 50 randomly chosen CD3+ cell density
curves by a surgeon with limited experience in pathology
(MAA) and by two experienced pathologists (JFE & CJ).Table 2 Discrepancies between the LQLI patterns for
CD3+ and CD45R0+ cells
Number of patients CD45R0+ CD3+
4 Pattern 2 Pattern 3
1 Pattern 1 Pattern 2
6 Pattern 3 Pattern 2
2 Pattern 2 Pattern 1Interobserver reproducibility was excellent (kappa = 0.93).
The mean time required for LQLI and classification of the
LI pattern by a pathologist was less than 2 minutes.
Prognostic value of LQLI pattern
After a median follow-up of 61 months (range, 5 to
113), 24 patients (20.5%) had died or relapsed, and 93
patients (79.5%) were alive without recurrence.
Univariate analysis showed that pT stage and pN sta-
tus, the total number of lymph nodes, vascular embolism
and perineural invasion were significant prognostic fac-
tors. LI, assessed by either CD3 count on TMA or by
LQLI, was also a prognostic factor. Ten patients had
CRC with high levels of MSI. Four of these patients
had LQLI pattern 1, five had LQLI pattern 2 and one had
LQLI pattern 3. None of the patients with high-MSI
tumors relapsed, but MSI status was not identified as a
significant prognostic value in this series of 117 patients.
These results and the corresponding three- and five-year
DFS results for each variable are reported in Table 3.
On multivariate analysis, LQLI pattern for CD3+ cells
(HR: 6.02; 95% CI: 2.74-13.18; P < 0.001) and metastatic
lymph node ratio (HR: 6.14; 95% CI: 2.32-16.2; P < 0.001)
were independently associated with DFS (Table 4).
Patients with high CD3+ cell densities on TMA had a
Figure 4 Distribution of CD3+ density according to the LQL
pattern.
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(92% and 90% versus 80% and 74% at 3 and 5 years;
P = 0.04; Figure 6). However, this factor was not sig-
nificant in multivariate analysis. Patients displaying
pattern 3 had worse outcomes than those displaying
pattern 1 or 2, regardless of the antibody (directed
against CD3 or CD45R0) used. With immunostaining
for CD3, three- and five-year DFS was 96% and 96%,
respectively, in patients with pattern 1, 90% and 86%
in patients with pattern 2, and 59% and 45% in
patients with pattern 3 (Figure 7).
Discussion
Many studies have already demonstrated the prognostic
value of lymphoid infiltration (LI) in CRC [3-5,11-13].
However, LI evaluation is still not used in daily practice
to determine whether a patient should receive adjuvantFigure 5 The ratio of the maximal and minimal CD3+ cells density wa
when evaluated more than 1.5 mm away from the tumor invasive front.treatment. Automated counts on virtual immune-stained
slides from patients with CRC have already been investi-
gated in other studies [12,13]. We developed an auto-
mated method of LI evaluation suitable for use in
routine clinical practice.
Our automated method has several specific features
accounting for its robustness and high level of reprodu-
cibility. The size of area analyzed (more than 14 times
the area of a TMA core) limits the impact of count va-
riability due to the heterogeneity of LI. Furthermore,
taking into account the demonstration, by Gallon et al.,
of the prognostic value of lymphocyte density in a region
adjacent to the tumor, the method developed here
includes both tumor tissue and the surrounding non
tumor tissue [13]. Finally, we decided to focus on the
variation of lymphocyte density across the invasive front,
from the non tumor region to the centre of the tumor,
rather than obtaining a mean value for one or two areas.
Interestingly, we were able, with a sample of 117 patients
with stage II or III CRC, to identify three different curve
patterns and to associate these patterns with long-term
outcome. One of the original findings of this study was
the presence of a peak of lymphocyte density around the
invasive front of the tumor in the curves or more than
half (61%) the study population. This finding is reminis-
cent of the high lymphocyte densities found at the inva-
sive margin of colorectal liver metastases, which are also
associated with a favorable outcome [20].
Lymphocyte density has been assessed by several
methods, including the counting of lymphocytes on
H&E-stained sections and immunostaining. It has been
evaluated on TMA and on whole slides [5,11-13,21].
Immunostained slides have been evaluated by a patho-
logist [22] or by dedicated software. A recent study
confirmed that the results of automated counting of
tumor-infiltrating lymphocytes based on image analysis
are closely correlated with the semi-quantitative resultss evaluated for all tumors. The variation was significantly lower
Table 3 Univariate analysis of pathological variables and two automated techniques (CD3+ cell counts from TMA and
LQLI) for disease-free survival
Clinical & pathological variables No. % 3-yr DFS 5-yr DFS HR 95% CI P
TNM stage 2.97 1.29-6.81 0.009
II 78 67 91 87
III 39 33 74 67
Metastatic LNR ratio 4.49 1.81-11.13 <0.001
≤0.2 102 87 89 85
>0.2 15 13 58 58
Vascular embolism 4.05 1.75-9.37 0.001
Yes 41 35 73 66
No 76 65 92 89
Perineural invasion 2.96 1.28-6.85 0.01
Yes 25 21 67 60
No 92 79 90 86
MSI status 1.36 0.89-2.34 0.11
MSI - 107 91 84 80
MSI + 10 9 No event No event
Lymphocyte density (CD3+ cells/mm²) with TMA 2.54 1.1-6.4 0.04
High [CD3+] 50 43 92 90
Low [CD3+] 67 57 80 74
CD3+ LQLI pattern 4.75 2.33-9.68 <0.0001
Pattern 1 24 20 96 96
Pattern 2 71 61 90 86
Pattern 3 22 19 59 45
CD45R0+ LQLI pattern
Pattern 1 23 19 96 96 3.85 1.09-7.77 <0.001
Pattern 2 70 60 90 85
Pattern 3 24 21 62 44
LNR lymph node ratio, HR hazard ratio, CI confidence interval, DFS disease-free survival.
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evaluate the percentage of the study area that is immu-
noreactive [11] or to identify lymphocytes by segmenta-
tion [12]. Such segmentation-based analysis may prove
difficult if the lymphocytes are located close together
[21]. We obtained identical patterns for analyses of the
percentage of the area displaying immunoreactivity and
for analyses based on the identification of positive cells.
In most studies, receiver operating characteristic
(ROC) curve analysis, with survival as the end-point, is
used to determine the cutoff values. This method is
problematic in that the mean values obtained cannot beTable 4 Multivariate analysis of disease-free survival
Variable Multivariate analysis
HR 95% CI P
Metastatic LNR 6.14 2.32-16.2 <0.001
CD3+ LQL pattern 6.02 2.74-13.18 <0.001
LNR lymph node ratio, HR hazard ratio, CI confidence interval.used for patients of other series or in routine practice.
This drawback does not apply to LQLI patterns, which
are not dependent on the definition of a single thresh-
old value. The LQLI method had a better prognostic
value than counts based on the use of TMA techno-
logy, and the results obtained were independent of the
analysis area. The LQLI method was also feasible for
all tumor subtypes, provided that the invasive front
was included in the paraffin-embedded block. The only
processes requiring direct human intervention in the
LQLI method are the positioning of the rectangle for
analysis on the virtual slides and determination of the
curve pattern. Interobserver reproducibility was excel-
lent (kappa = 0.93).
Microsatellite instability has been shown to be predic-
tive of a favorable outcome, even in the absence of adju-
vant therapy, in colorectal cancer. Tumors displaying
microsatellite instability are known to have rich lym-
phoid infiltrates [24-26]. It is therefore important to
consider microsatellite status when assessing LI and
Figure 6 Kaplan Meier disease-free survival curve according to CD3+ densities measured on TMA cores.
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MSI-positive tumors had a low density of lymphocytes
both in and around the tumor (pattern 3). CD3+ cell
density was higher in the MSI+ group than in tumors
without MSI, and the other nine patients displayed LI
patterns 1 and 2, but these differences were not statisti-
cally significant. No relapses were recorded in the MSI-Figure 7 Kaplan Meier disease-free survival curve according to CD3+positive group, but MSI status was not identified as signifi-
cantly predictive of disease-free survival, possibly due to
the small number of patients with MSI-positive tumors.
Another important feature of LI is the location of lym-
phocytes within the tumor. Indeed, the infiltration of
cancer cell networks by CD8+ T cells has been reported
to be of prognostic value in colorectal cancer [27].LQLI pattern.
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survival in patients with non-small cell lung cancer [28].
We did not investigate the prognostic significance of the
location of the lymphocytes within the tumor (stroma
versus epithelial tumor cells) with our method. Little is
currently known about the precise role of lymphocyte lo-
cation and its impact on prognosis, and further investiga-
tions and confirmation in a different subset of solid
tumors are required before this method can be adopted as
a standard approach.
By contrast, a number of studies have investigated the
nature of the lymphocytes infiltrating tumors. Galon
et al. analyzed four lymphoid markers (CD3, CD8,
CD45R0, granzyme B) and found that combined analysis
of CD3+ and CD45RO+ lymphocyte densities in the cen-
ter of the tumor and the invasive margin had the best
prognostic value [13]. In an independent series, FoxP3
was the only prognostic marker identified, with CD45RO
and CD8 significant only in univariate analysis [12]. Both
these studies were performed on tissue arrays. The in-
nate immune response may also play an important role
in tumor control, as shown by the prognostic value of
the density of tumor-infiltrating NK cells and macro-
phages [29]. Moreover, the respective proportions and
the location of the various leukocyte subpopulations
with respect to the tumor may be important, as already
demonstrated for breast carcinomas [30].Conclusion
In conclusion, we describe an original method (LQLI)
for the evaluation of LI, plotted as a function of the dis-
tance from the invasive front of the tumor. This method
is reproducible for a given tumor, and has a better prog-
nostic value than CD3+ cell counts on TMA, which is
highly variable and less reliable at the individual level. It
is easy to use, and results for virtual slides can be
obtained in less than two minutes. The LQLI method
thus appears to be a powerful tool for investigations of
the anti-tumor immune response. Further studies are
required to determine which leukocyte subpopulation
has the best prognostic value in large series of patients.
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